

Curriculum Vitae
Hadley Spencer, FNP-C

Practice Address:

Oncology Specialists of Charlotte
2630 E 7th Street, Suite 210
Charlotte, NC 28204
hspencer@oncologycharlotte.com

Site Affiliations:

DJL Clinical Research, PLLC
10370 Park Road, Suite 200
Charlotte, NC 28210

Education:

2011	Bachelor of Science in Nursing Clemson University Clemson, South Carolina
2015	Master of Science Francis Marion University Florence, South Carolina Specialty: Family Nurse Practitioner

Professional Experience:

2011-2015	Registered Nurse Colonial Family Practice
2012-2016	Clinical Supervisor Urgent Care
2015-2016	Family Nurse Practitioner Colonial Family Practice
2016-Present	Family Nurse Practitioner Oncology Specialists of Charlotte

Certifications:

Present - 2020	AHA Advanced Cardiovascular Life Support
Present - 2020	AHA BLS

Professional Organizations:

Oncology Nursing Society
American Academy of Nurse Practitioners

Clinical Research:

Sub- Investigator – ARMO Biosciences Cypress 1: A Randomized Phase 2 Trial of AM0010 in Combination with Pembrolizumab vs. Pembrolizumab Alone as First-line Therapy in Patients with Metastatic Non-Small Cell Lung Cancer whose Tumors Have High PD-L1 Expression.

Curriculum Vitae
Hadley Spencer, FNP-C

Sub- Investigator – Incyte: A phase 2, open-label, single-arm, multicenter study to evaluate the efficacy and safety of INCB054828 in subjects with advanced/metastatic or surgically unresectable cholangiocarcinoma including FGFR2 translocations who failed previous therapy.

Sub- Investigator – Amgen: A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects With Non-myeloid Malignancies at High Risk for FN and Receiving Neulasta® (pegfilgrastim) Onpro® kit or Other Physician Choice Options for Prophylaxis of FN.

Sub- Investigator – Amgen: An Open-label Phase 2 Study of Carfilzomib Plus Dexamethasone To Assess Tolerability and Adherence in Subjects With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers.

Sub- Investigator –Boehringer Ingelheim Pharmaceuticals, Inc: XENERA™-1: A multi-centre, double-blind, placebo-controlled, randomised phase II trial to compare efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in post-menopausal women with HR+ / HER2- metastatic breast cancer and non-visceral disease.

Sub- Investigator – Regeneron: Cemiplimab Survivorship Epidemiology (CASE) Study

Sub- Investigator – Astrazeneca: An Open Label, Multi-center, IRESSA™ Clinical Access Program of Gefitinib 250 mg (IRESSA™) for the continued treatment of patients in the United States who are currently benefiting or have benefited from gefitinib treatment. 2019

Sub- Investigator – Incyte: Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207). 2019


Sub- Investigator – Novocure: LUNAR: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapies for treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure


Sub- Investigator – SecuraBio Inc: A Disease Registry Encompassing the Care of Patients with Multiple Myeloma on Panobinostat (RECOMM)

Sub-Investigator – Daily Body Restore: A Double-blind, Placebo-controlled Evaluation of a Proprietary Dietary Supplement Containing Probiotics and Digestive Enzymes for Alleviating Chemotherapy-Associated Adverse Events in Colorectal Cancer

Sub-Investigator – GSK: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease has Remained Stable or Responded to First-Line Platinum-Based Chemotherapy with Pembrolizumab for Stage IIIB or IV Non-Small Cell Lung Cancer

My signature verifies the information in these curriculum vitae is accurate and updated appropriately.


Signature


Date